Hikma Launches Nasal Naloxone Spray In US
Emergency Opioid Overdose Treatment Approved Through 505(b)(2) Pathway
Hikma has delivered on one of its key US launches for 2021 by introducing its Kloxxado naloxone 8mg nasal spray for the emergency treatment of known or suspected opioid overdose, after the 505(b)(2) product was approved by the FDA earlier this year.
You may also be interested in...
Fresh Competition Coming For Narcan In US
Further US hybrid and generic rivals to Narcan are in the works, with Amphastar having just received an FDA nod for its naloxone nasal spray in a proprietary device as Amneal files an ANDA for a further generic version.
Hikma Adds Another Celltrion Biosimilar To MENA Collaboration
Hikma has further expanded its portfolio of biosimilars in the MENA region with the addition of Celltrion’s Vegzelma bevacizumab rival to Avastin. Meanwhile, Hikma has also just launched a new pre-filled syringe version of naloxone in the US.
Hikma And Adalvo Ally On Nasal Spray For MENA
Hikma and Adalvo have struck a licensing deal that will see Hikma commercialize a “high value” nasal spray treatment for allergic rhinitis in the MENA region.